MedTrace Logo

A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASC47 in Combination With Semaglutide

NCT06972992 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2025-12-18

No results posted yet for this study

Summary

This will be a phase I, randomized, double-blind, placebo-controlled. This study will be conducted in three periods: the screening period, the treatment period, and the follow-up period.

Conditions

Interventions

DRUG

ASC47 +Semaglutide

ASC47 single subcutaneous injection + Semaglutide QW for 4 weeks

DRUG

Placebo+Semaglutide

Placebo single subcutaneous injection + Semaglutide QW for 4 weeks

Sponsors & Collaborators

  • Ascletis Pharma (China) Co., Limited

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-04-18
Primary Completion
2025-09-22
Completion
2025-09-22
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06972992 on ClinicalTrials.gov